Claims
- 1. A method of inhibiting gastric acid secretion in mammals in need of gastric acid secretion inhibition comprising administering to said mammal a pharmaceutically effective dose of a direct acting 5-HT.sub.1A agonist which is an aryloxypropanolamine or a pharmaceutically acceptable acid addition salt thereof.
- 2. The method according to claim 1 wherein said mammals are humans.
- 3. The method according to claim 2 wherein said aryloxypropanolamine has the Formula: ##STR38## where Ar is an optionally mono- or disubstituted phenyl or naphthalene ring where the substituents are selected from allyl, C.sub.1 -C.sub.4 alkyl, O(C.sub.1 -C.sub.4 alkyl), --(C.sub.1 -C.sub.3 alkylidene)-O-(C.sub.1 -C.sub.4 alkyl), O-allyl, CN, NHCO(C.sub.1 -C.sub.3 alkyl), --CH.sub.2 CONH.sub.2, trifluoromethyl, hydroxy, halo, (C.sub.1 -C.sub.4 alkyl)S(O).sub.p --, where p is 0, 1, or 2; and a C.sub.3 -C.sub.8 cycloalkyl or a bicycloalkyl group of the Formula; ##STR39## where a and c are independently 1-5, b is 0-5, and
- (a+c) is greater than 2; and G' is a bond or C.sub.1 -C.sub.4 alkylidene; or where Ar is the group ##STR40## Z is a straight or branched C.sub.3 -C.sub.10 alkyl; C.sub.4 -C.sub.10 alkenyl; C.sub.4 -C.sub.10 alkynyl group; a phenyl(C.sub.2 -C.sub.10) alkyl where the phenyl moiety may be substituted with a halo, C.sub.1 -C.sub.4 alkyl, trifluoromethyl, hydroxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl-S(O).sub.p - where p is 0, 1, or 2; a group G-V where G is independently a bond or C.sub.1 -C.sub.4 alkyl or phenyl, and V is C.sub.4 -C.sub.8 cycloalkyl optionally substituted with a C.sub.1 -C.sub.4 alkyl or phenyl; a -(C.sub.1 -C.sub.4 alkylidene)-T-(C.sub.1 -C.sub.4 alkyl) where T is --O--, --S--, --SO--, or --SO.sub.2 --; or a bicycloalkyl group having the Formula: ##STR41## where G is as defined above and a and c are independently 1-5, b is 0-5, and (a+c) is greater than 2; R.sup.10.
- 4. The method according to claim 3 wherein Z is a straight or branched chain C.sub.4 -C.sub.10 alkane, alkene, or alkyne group, or an optionally substituted phenyl(C.sub.2 -C.sub.10) alkyl where the phenyl ring may be substituted with a C.sub.1 -C.sub.4 alkyl, CF.sub.3, OH, C.sub.1 -C.sub.4 alkoxy, halo or --S(O).sub.p C.sub.1 -C.sub.4 alkyl where p is 0, 1, or 2.
- 5. The method according to claim 4 wherein Ar is ##STR42## where R.sup.11 is hydrogen, C.sub.1 -C.sub.4 alkyl, trifluoromethyl, hydroxy, (C.sub.1 -C.sub.4 alkyl)-O-(C.sub.1 -C.sub.4 alkyl)-S(O).sub.p - or halo and p is 0, 1, or 2; and
- R.sup.12 is C.sub.3 -C.sub.8 cycloalkyl.
- 6. The method according to claim 5 where R.sup.12 is cyclopentyl.
Parent Case Info
This is a division of prior application Ser. No. 08/219,157, filed Mar. 29, 1994, now U.S. Pat. No. 5,457,120 which is a division of prior application Ser. No. 08/068,723, filed May 26, 1993, now U.S. Pat. No. 5,340,838, which is a division of prior application Ser. No. 07/898,991, filed Jun. 15, 1992, now U.S. Pat. No. 5,258,379, which is a division of prior application Ser. No. 07/707,357, filed May 29, 1991, now U.S. Pat. No. 5,158,956, which is a continuation-in-part of application Ser. No. 07/519,388, filed May 4, 1990, now U.S. Pat. No. 5,096,908.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
2997422 |
Tedeschi et al. |
Aug 1961 |
|
3551493 |
Ruschig et al. |
Dec 1970 |
|
3961073 |
Snyder |
Jun 1976 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
345056 |
Dec 1989 |
EPX |
Non-Patent Literature Citations (3)
Entry |
Chemical Abstracts, Puscas et al., Synergistic drug for the treatment of gastritis, gastroduodenitis and gastroduodenal ucler. 109: 98864. (1988). |
Bulbring, E., et. al., Adv. Pharmac., 6A, 323-333 (1968). |
Blundell, J. E., Neuropharmacology, 23, 1537-1551 (1984). |
Divisions (4)
|
Number |
Date |
Country |
Parent |
219157 |
Mar 1994 |
|
Parent |
68723 |
May 1993 |
|
Parent |
898991 |
Jun 1992 |
|
Parent |
707357 |
May 1991 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
519388 |
May 1990 |
|